Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor... see more

Recent & Breaking News (OTCQB:NWBO)

NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum

PR Newswire January 23, 2015

NW Bio To Present At Biotech Showcase Conference

PR Newswire January 8, 2015

NW BIO RECAPS 2014 PROGRESS, PROVIDES DCVAX-DIRECT TRIAL UPDATE AT OPPENHEIMER'S 25TH ANNUAL HEALTHCARE CONFERENCE

PR Newswire December 11, 2014

NW BIO ANNOUNCES FINANCINGS TOTALING $35 MILLION TO EXPAND AND ACCELERATE DCVAX®-L AND DCVAX®-DIRECT PROGRAMS

PR Newswire November 19, 2014

NW BIO MAKING A JOINT POSTER PRESENTATION ON ITS DCVAX-DIRECT TRIAL AT THE 29TH ANNUAL SITC MEETING

PR Newswire November 7, 2014

The most undervalued, yet comprehensive cancer immunotherapy in development?

Accesswire November 3, 2014

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Northwest Biotherapeutics, Inc.

PR Newswire October 28, 2014

DCVAX®-L HOSPITAL EXEMPTION PROGRAM NOW UNDER WAY IN GERMANY

PR Newswire October 14, 2014

NW BIO ANNOUNCES $11.5 MILLION FINANCING

PR Newswire October 7, 2014

NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM)

PR Newswire September 16, 2014

NW BIO CEO TO PRESENT AT SMi's 3rd ANNUAL CANCER VACCINES CONFERENCE IN LONDON

PR Newswire September 15, 2014

NW BIO TO PRESENT UPDATES AT RODMAN RENSHAW 16TH ANNUAL GLOBAL INVESTMENT CONFERENCE

PR Newswire September 8, 2014

NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING

PR Newswire August 19, 2014

NW BIO ANNOUNCES PRICING OF $17.5 MILLION OFFERING OF CONVERTIBLE NOTES

PR Newswire August 14, 2014

NW BIO CORRECTS ONGOING FALSE CLAIMS BY FEUERSTEIN ABOUT PHASE III TRIAL OF DCVAX®-L, AND INTERIM ANALYSIS

PR Newswire August 13, 2014

NW BIO PROVIDES UPDATE ABOUT PHASE III DCVAX®-L TRIAL FOR GBM AND "INFORMATION ARM" COMPASSIONATE USE PATIENTS

PR Newswire August 11, 2014

NW BIO OBTAINS APPROVALS FOR ENHANCEMENTS OF PHASE III TRIAL OF DCVAX®-L FOR GBM BRAIN CANCER

PR Newswire August 11, 2014

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Northwest Biotherapeutics, Inc.

Business Wire July 30, 2014

Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Northwest Biotherapeutics, Inc. Stockholders

Business Wire July 23, 2014